Not Signed In -
Occipital Neuralgia |
|
|
Clinical Trial: Study of Pregabalin Therapy for Pain Relief in Subjects with Post-Herpetic Neuralgia
This study is currently recruiting patients.
Verified by Pfizer September 2005
|
Purpose
The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia
| Condition | Intervention | Phase |
|---|---|---|
| Post-Herpetic Neuralgia | Drug: pregabalin | Phase IV |
MedlinePlus related topics: Pain; Peripheral Nerve Disorders; Shingles
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects with Post Therapeutic Neuralgia (Phn) Treated with Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo
Further Study Details:
Primary Outcomes: Onset meaningful pain reduction
Expected Total Enrollment: 255
Expected Total Enrollment: 255
Study start: October 2004
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Diagnosis of PHN with pain present for at least three months after the healing of a Herpes Zoster skin lesion.
- Subjects must have completed the Daily Pain Rating Scale in the electronic diary at least 4 times during screening and have an average daily pain rating score of greater than or equl to 4 during the 7 +/- 3 days prior to randomization (Visit 2).
Exclusion Criteria:
- History of neurolytic or neurosurgical therapy for PHN.
- Presence of any severe pain associated with conditions other than PHN that may confound the assessment or self-evaluation of the pain due to PHN.
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00159666
Pfizer CT.gov Call Center 1-800-718-1021
Arizona
Pfizer Investigational Site, Phoenix, Arizona, 85023, United States; Recruiting
Arkansas
Pfizer Investigational Site, Little Rock, Arkansas, 72205, United States; Recruiting
Florida
Pfizer Investigational Site, Palm Beach Gardens, Florida, 33410, United States; Recruiting
Ohio
Pfizer Investigational Site, Toledo, Ohio, 43623-3074, United States; Recruiting
Oregon
Pfizer Investigational Site, Portland, Oregon, 97239, United States; Recruiting
Pennsylvania
Pfizer Investigational Site, Allentown, Pennsylvania, 18103, United States; Recruiting
Texas
Pfizer Investigational Site, Houston, Texas, 77058-3600, United States; Recruiting
Washington
Pfizer Investigational Site, Seattle, Washington, 98104, United States; Recruiting
Wisconsin
Pfizer Investigational Site, Madison, Wisconsin, 53792-1615, United States; Recruiting
Germany
Pfizer Investigational Site, Leipzig, 04229, Germany; No longer recruiting
Pfizer Investigational Site, Frankfurt, 60311, Germany; Recruiting
Pfizer Investigational Site, Duesseldorf, 40225, Germany; Recruiting
Pfizer Investigational Site, Berlin, 12627, Germany; Recruiting
Pfizer Investigational Site, Bochum, 44892, Germany; Recruiting
Pfizer Investigational Site, Goeppingen, 73033, Germany; Recruiting
Pfizer Investigational Site, Hattingen, 45525, Germany; Recruiting
Pfizer Investigational Site, Wiesbaden, 65195, Germany; Recruiting
Pfizer Investigational Site, Jena, 07743, Germany; Recruiting
Pfizer Investigational Site, Nuernberg, 90489, Germany; Recruiting
Italy
Pfizer Investigational Site, Pisa, 56126, Italy; Recruiting
Pfizer Investigational Site, Perugia, 06123, Italy; Recruiting
Pfizer Investigational Site, L''''Aquila, 67100, Italy; Recruiting
Pfizer Investigational Site, Cosenza, 87100, Italy; No longer recruiting
Pfizer Investigational Site, Roma, 00128, Italy; Recruiting
Spain
Pfizer Investigational Site, Sevilla, 41013, Spain; Recruiting
Pfizer Investigational Site, Salamanca, 37007, Spain; Recruiting
Pfizer Investigational Site, Sevilla, 41041, Spain; Recruiting
Pfizer Investigational Site, Valencia, 46014, Spain; Recruiting
Spain, Madrid
Pfizer Investigational Site, Leganes, Madrid, 28911, Spain; Recruiting
United Kingdom
Pfizer Investigational Site, Oldham, Lancashire, OL1 2JH, United Kingdom; Recruiting
United Kingdom, Cleveland
Pfizer Investigational Site, Middlesbrough, Cleveland, TS4 3BW, United Kingdom; Recruiting
United Kingdom, SURREY
Pfizer Investigational Site, Addlestone, SURREY, KT15 2BH, United Kingdom; Recruiting
United Kingdom, Sussex
Pfizer Investigational Site, Chicester, Sussex, P019 4SE, United Kingdom; Recruiting
Study chairs or principal investigators
Pfizer CT.gov Call Center, Study Director, Pfizer
More Information
Study ID Numbers: A0081004
Last Updated: September 11, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00159666
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 11, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00159666
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
